Scribner, 492 pp., $28.00
On April 19 of this year, in South Africa, thirty-nine drug companies jointly withdrew from a lawsuit aimed at protecting their patents. The suit had been brought by the pharmaceutical giants in response to a law passed in 1997, which allowed the South African health ministry to buy copies of branded drugs; the law gave the go-ahead to local and foreign manufacturers to ignore patents and sell generic copies at a price local markets could bear. The withdrawal of the pharmaceutical companies' action was a significant moral victory for the South African administration, which governs a population in which deaths from AIDS are said to run at five thousand a week.
Review, 4977 words
To read the full text of this piece, please choose one of the following options:
|
If you are already a subscriber to the Review's electronic edition, please sign in: |
To subscribe to the electronic edition, please press the button below. |
To purchase access to this article for $3, please press the button below. |